Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.

Brain and behavior - 1 Jun 2024

Huang Qiang, Zhang Qin, Cao Bei

Abstract excerpt

BACKGROUND: In addition to lowering cholesterol levels, the proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has a variety of effects, including anti-neuroapoptosis. However, the effects of PCSK9 inhibitors on neurodegenerative diseases are controversial. Therefore, we used drug-targeted Mendelian randomization (MR) analysis to investigate the effects of PCSK9 inhibitors on different neurodegenerative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyotrophic Lateral Sclerosis
Share to Genome-Wide Association Study

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Mendelian Randomization Analysis

Share to Neurodegenerative Diseases

Share to Parkinson Disease

Share to Proprotein Convertase 9

Source

Open in PubMed Open full text

Identifiers

PMID: 38837845
DOI: 10.1002/brb3.3543
PMCID: PMC11151217

Genes

PCSK9
HMGCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.PMID 38837845Read ↗

The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug TargetingSemantic proximity Read ↗

Genetic Associations of Lipid-Lowering Drugs and Parkinson’s Disease: A Mendelian Randomization StudySemantic proximity Read ↗

Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.Semantic proximity Read ↗

PCSK9 Inhibitors Do Not Increase Cognitive RiskSemantic proximity Read ↗

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study.Semantic proximity Read ↗

Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and Women: A Drug‐Target Mendelian Randomization StudySemantic proximity Read ↗

PCSK9 Inhibitors and Bipolar Disorder: A Drug Target Mendelian Randomization Study.Semantic proximity Read ↗

Causal relationship between cholesterol-lowering therapy and Alzheimer Disease: evidence from genetic correlation and Mendelian randomization studySemantic proximity Read ↗

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.Semantic proximity Read ↗

Lipid lowering and Alzheimer disease risk: A mendelian randomization study.Semantic proximity Read ↗

Astrocytic HMGCR-Mediated Cholesterol Alleviated Parkinson's Disease Phenotypes by Inhibiting NF-κB Neuroinflammation.Semantic proximity Read ↗

Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive FunctionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.